Showing 2971-2980 of 4063 results for "".
- Allergan to Present Data From Durysta and Xen Gel Stent at the 2022 American Glaucoma Society (AGS) Annual Meetinghttps://modernod.com/news/allergan-to-present-data-from-durysta-and-xen-gel-stent-at-the-2022-american-glaucoma-society-ags-annual-meeting/2480663/Allergan announced new data to be presented from it
- Refractive Surgery Council Reports 32% YTD Increase in Laser Vision Correction Procedure Volume over 2020https://modernod.com/news/refractive-surgery-council-reports-32-ytd-increase-in-laser-vision-correction-procedure-volume-over-2020/2480591/T
- Envision Conference Announces 2022 In-Person Date, Calls for Submissionshttps://modernod.com/news/envision-conference-announces-2022-in-person-date-calls-for-submissions/2480569/
- CORE Names “Top 10 of 2021” Scientific Papers for Eye Care Communityhttps://modernod.com/news/core-names-top-10-of-2021-scientific-papers-for-eye-care-community/2480525/In a year like no other, the Centre for Ocular Research & Education (CORE) has published a record 66 scientific and clinical educational papers on topics that advance academic and clinical knowledge in optometry and ophthalmology. The organization today announced its “Top 10 o
- Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europehttps://modernod.com/news/nicox-is-granted-patent-for-blepharitis-product-candidate-ncx-4251-in-europe/2480459/Nicox SA announced that patent EP 3,769,753, expiring in 2040 and covering the company’s product candidate in development for blepharitis, NCX 4251, has been issued by the European Patent Office (EPO). The patent covers ophthalmic suspensions comprising a specific form of fluticas
- AAO: Top Four Issues Threatening Ophthalmology’s Financial Stabilityhttps://modernod.com/news/aao-top-four-issues-threatening-ophthalmologys-financial-stability/2480440/<
- Refractive Surgery Council Reports 48% YTD Increase in Laser Vision Correction Procedure Volume Over 2020https://modernod.com/news/refractive-surgery-council-reports-48-ytd-increase-in-laser-vision-correction-procedure-volume-over-2020/2480407/T
- Heru Releases re:Vive 2.0: A Single Wearable Platform with 6 Vision Diagnostic Modalities that Support 5 CPT Codeshttps://modernod.com/news/heru-releases-revive-20-a-single-wearable-platform-with-6-vision-diagnostic-modalities-that-support-5-cpt-codes/2480396/Heru announced it is expanding the capabilities of re:Vive by Heru, the company’s wearable gamified diagnostic solution, to include three new testing modalities: Color Vision CPT 92283, Contrast Sensitivity, and Dark Adaptation CPT 92284. “Since the inception of Heru, our go
- Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of Iluvien to Significantly Reduce Treatment Burden in Patients with DMEhttps://modernod.com/news/recent-24-month-real-world-paladin-data-demonstrate-the-ability-of-iluvien-to-significantly-reduce-treatment-burden-in-patients-with-dme/2480348/Alimera Sciences announced a data presentation at the American Society of Retina Specialists (ASRS) demonstrating significant reductions in treatment burden in patients receiving Iluvien for diabetic macular edema (DME). The real-world data from the phase 4 PALADIN study
- New Tepezza Data to be Presented at the American Academy of Ophthalmology 2021 Annual Meetinghttps://modernod.com/news/new-tepezza-data-to-be-presented-at-the-american-academy-of-ophthalmology-2021-annual-meeting/2480344/